Literature DB >> 28622247

Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

Ulrika Asenbaum1, Ahmed Ba-Ssalamah, Mattias Mandorfer, Richard Nolz, Julia Furtner, Thomas Reiberger, Arnulf Ferlitsch, Klaus Kaczirek, Michael Trauner, Markus Peck-Radosavljevic, Andreas G Wibmer.   

Abstract

OBJECTIVE: The aim of this study was to investigate the impact of portal hypertension (PH) on gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) and assess diagnostic and prognostic implications in comparison to established imaging features of PH.
MATERIALS AND METHODS: Institutional review board-approved retrospective study of 178 patients (142 men; median age, 59.4 years) with chronic liver disease undergoing MRI and hepatic venous pressure gradient (HVPG) measurement between January 2008 and April 2015. Magnetic resonance imaging was assessed for established features of PH (splenic and portal vein diameters, portosystemic collaterals, ascites) and for features on 20 minutes delayed T1-weighted gadoxetic acid-enhanced MRI, that is, relative liver enhancement (RLE), biliary contrast excretion, or portal vein hyperintensity or isointensity (ie, portal vein hyperintensity sign, PVHS). Statistics encompassed linear regression, logistic regression, and survival analysis.
RESULTS: There was an inverse correlation between HVPG and RLE (r = 0.18, P < 0.0001). On univariate analysis, clinically significant PH (ie, HVPG ≥ 10 mm Hg, n = 109) and severe PH (ie, HVPG ≥ 12 mm Hg, n = 99) were associated with delayed biliary contrast excretion (n = 33) and the PVHS (n = 74) (P < 0.01 for all). Multivariate analysis demonstrated significant associations between the PVHS and severe PH (odds ratio [OR], 3.33; P = 0.008), independently of spleen size (OR, 1.26; P = 0.002), portosystemic collaterals (n = 81; OR, 5.46; P = 0.0001), and ascites (n = 88; OR, 3.24; P = 0.006). Lower RLE and the PVHS were associated with lower 3-year, transplantation-free survival (hazards ratios, 0.98 and 3.99, respectively, P = 0.002 for all), independently of the Child-Pugh and Model for End-Stage Liver Disease scores.
CONCLUSIONS: The presence of the PVHS on gadoxetic acid-enhanced MRI is an independent indicator of severe PH and may enable more accurate diagnosis. This feature and decreased hepatic contrast uptake may also comprise prognostic information.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28622247     DOI: 10.1097/RLI.0000000000000366

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  5 in total

Review 1.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

Review 2.  Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.

Authors:  Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-02-01       Impact factor: 5.315

3.  Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR.

Authors:  Carla Caparroz; Alejandro Forner; Jordi Rimola; Anna Darnell; Ángeles García-Criado; Juan Ramón Ayuso; María Reig; Jordi Bruix; Carmen Ayuso
Journal:  Radiol Oncol       Date:  2022-08-14       Impact factor: 4.214

Review 4.  Bibliometric-analysis visualization and review of non-invasive methods for monitoring and managing the portal hypertension.

Authors:  XiaoHan Sun; Hong Bo Ni; Jian Xue; Shuai Wang; Afaf Aljbri; Liuchun Wang; Tian Hang Ren; Xiao Li; Meng Niu
Journal:  Front Med (Lausanne)       Date:  2022-09-15

5.  Intracellular accumulation capacity of gadoxetate: initial results for a novel biomarker of liver function.

Authors:  Ute Lina Fahlenkamp; Katharina Ziegeler; Lisa Christine Adams; Sarah Maria Böker; Günther Engel; Marcus Richard Makowski
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.